Tresiba | Page 3 of 3

New Novo Nordisk Insulin Reduces Risk of Nighttime Hypoglycemia, New Studies Show

Novo Nordisk's ultra long-acting basal insulin Degludec significantly reduces risk of hypoglycemia during the night compared to insulin glargine, according to two long-term studies. The company announced the clinical results from two 52-week phase 3a treat-to-target studies comparing Degludec to insulin glargine in basal-bolus treatment of type 1 and type 2 diabetes...

Novo Nordisk’s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus

Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes. The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD)...

Novo Nordisk Presents Positive Phase 2 Data for Ultra-Long-Acting Insulin Degludec

According to a Novo Nordisk press release the company presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando FL...